Technical Analysis for ELEV - Elevation Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.59 | -3.75% | -0.14 |
ELEV closed up 4.78 percent on Wednesday, May 15, 2024, on 29 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -3.75% | |
| Shooting Star Candlestick | Bearish | -3.75% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.75% | |
| MACD Bullish Signal Line Cross | Bullish | -3.75% | |
| Bollinger Band Squeeze | Range Contraction | -3.75% | |
| Gapped Up | Strength | -3.75% | |
| Up 3 Days in a Row | Strength | -3.75% | |
| 20 DMA Resistance | Bearish | 0.84% | |
| Shooting Star Candlestick | Bearish | 0.84% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.84% |
| Alert | Time |
|---|---|
| Possible NR7 | 4 minutes ago |
| 10 DMA Support | 28 minutes ago |
| Down 3% | about 1 hour ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 3 hours ago |
| Shooting Star Candlestick Entry | about 3 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.89 |
| 52 Week Low | 0.363 |
| Average Volume | 898,413 |
| 200-Day Moving Average | 2.01 |
| 50-Day Moving Average | 4.26 |
| 20-Day Moving Average | 3.73 |
| 10-Day Moving Average | 3.59 |
| Average True Range | 0.41 |
| RSI (14) | 47.09 |
| ADX | 15.32 |
| +DI | 19.50 |
| -DI | 18.64 |
| Chandelier Exit (Long, 3 ATRs) | 3.29 |
| Chandelier Exit (Short, 3 ATRs) | 4.42 |
| Upper Bollinger Bands | 4.20 |
| Lower Bollinger Band | 3.26 |
| Percent B (%b) | 0.5 |
| BandWidth | 25.18 |
| MACD Line | -0.20 |
| MACD Signal Line | -0.20 |
| MACD Histogram | 0.0038 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.17 | ||||
| Resistance 3 (R3) | 4.19 | 4.06 | 4.09 | ||
| Resistance 2 (R2) | 4.06 | 3.95 | 4.05 | 4.07 | |
| Resistance 1 (R1) | 3.90 | 3.88 | 3.98 | 3.88 | 4.04 |
| Pivot Point | 3.77 | 3.77 | 3.82 | 3.76 | 3.77 |
| Support 1 (S1) | 3.61 | 3.66 | 3.69 | 3.59 | 3.42 |
| Support 2 (S2) | 3.48 | 3.59 | 3.47 | 3.39 | |
| Support 3 (S3) | 3.32 | 3.48 | 3.37 | ||
| Support 4 (S4) | 3.30 |
